AHCL vs BALAXI: Stock Comparison

Anlon Healthcare Limited vs BALAXI PHARMACEUTICALS LIMITED

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Anlon Healthcare Limited is the larger company by market capitalisation. Anlon Healthcare Limited shows a higher ROE, faster revenue growth and lower leverage, while BALAXI PHARMACEUTICALS LIMITED shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Anlon Healthcare Limited and BALAXI PHARMACEUTICALS LIMITED on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AHCL is more favourable on 8 of 13 scored metrics and BALAXI on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
AHCL is the larger company
₹797 Cr vs ₹135 Cr
P/E Ratio
BALAXI has a lower P/E
12.63x vs 27.78x
P/B Ratio
BALAXI has a lower P/B
0x vs 3.46x
EPS
BALAXI has higher earnings per share
₹1.72 vs ₹0.61
Revenue Growth (TTM YoY)
AHCL has faster revenue growth
4% vs -25.76%
EPS Growth (TTM YoY)
AHCL has faster EPS growth
-54.8% vs -58.44%
Qtr Sales Growth
BALAXI has stronger quarterly sales growth
7.8% vs 4.01%
Qtr Profit Growth
AHCL has stronger quarterly profit growth
-36.9% vs -95.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAHCLBALAXI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAHCLBALAXI
Live Price₹15.01₹26.67
Day Change-0.46%1.14%
Volume28.27 L51,334
52-Week High₹161₹52.5
52-Week Low₹12.91₹15.2
Distance from 52W High-90.68%-49.2%

Valuation

MetricAHCLBALAXI
Market Cap₹797 Cr₹135 Cr
P/E Ratio27.78x12.63x
P/B Ratio3.46x0x
EPS₹0.61₹1.72
Book Value₹5.11₹41.98
Dividend Yield0%0%

Growth

MetricAHCLBALAXI
Revenue Growth (TTM YoY)4%-25.76%
EPS Growth (TTM YoY)-54.8%-58.44%
Qtr Sales Growth4.01%7.8%
Qtr Profit Growth-36.9%-95.5%

Profitability & Leverage

MetricAHCLBALAXI
ROE18.4%0.57%
ROCE20.8%13%
Net Margin22.18%0.52%
Operating Margin27.6%3.4%
Debt to Equity0.19x0.22x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAHCLBALAXI
Promoter Holding52.68%65.99%
FII Holding0.32% 0.09 pp0% 1.74 pp
DII Holding4.6% 0.11 pp2.56% 2.54 pp
Public Holding42.4% 0.2 pp31.45% 0.79 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Anlon Healthcare Limited and BALAXI PHARMACEUTICALS LIMITED.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.